NEET is a double-blind, placebo-controlled trial with 356 treatment-naïve patients randomized to receive 15 grams of D-tagatose three times daily with meals for a period of up to one year as an ...
Bethesda, MD, November 16, 2009 /PRNewswire/ - Spherix Incorporated (NASDAQ CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback